董事
Joshua S. Boger, Ph.D., is an American organic chemist, biotechnology entrepreneur, and corporate director, best known as the founder and former CEO of Vertex Pharmaceuticals Incorporated (VRTX).[[7]](https://en.wikipedia.org/wiki/Joshua_Boger)[[4]](https://www.xprize.org/people/joshua-boger) A pioneer of structure-based rational drug design, he led the development of important therapies including the HIV protease inhibitor amprenavir, the hepatitis C protease inhibitor telaprevir, and Kalydeco for cystic fibrosis during his tenure at Vertex, where he served as president from its founding in 1989, chief executive officer from 1992 to 2009, and chairman of the board from 1997 to 2006.[[7]](https://en.wikipedia.org/wiki/Joshua_Boger)[[1]](https://www.theexecutivepaper.com/healthcare/20240208/joshua-s-boger-ph-d-was-appointed-as-a-director-of-cervomed-inc-and-as-chair-of-the-board-by-the-board-of-directors-11568204/index.html) Before founding Vertex, Boger was Senior Director of Basic Chemistry at Merck Sharp & Dohme Research Laboratories, heading the Departments of Biophysical Chemistry and Medicinal Chemistry of Immunology & Inflammation.[[1]](https://www.theexecutivepaper.com/healthcare/20240208/joshua-s-boger-ph-d-was-appointed-as-a-director-of-cervomed-inc-and-as-chair-of-the-board-by-the-board-of-directors-11568204/index.html)[[4]](https://www.xprize.org/people/joshua-boger)
Boger currently serves as Chair of the Board of CervoMed Inc. (CRVO), having been appointed a director and chair of the board in February 2024, and is identified in corporate and academic references as Chair of the Board of CervoMed.[[1]](https://www.theexecutivepaper.com/healthcare/20240208/joshua-s-boger-ph-d-was-appointed-as-a-director-of-cervomed-inc-and-as-chair-of-the-board-by-the-board-of-directors-11568204/index.html)[[5]](https://hms.harvard.edu/faculty-staff/joshua-boger)[[6]](https://ir.cervomed.com/node/10611/pdf) He is also the Executive Chairman of Alkeus Pharmaceuticals, Inc., a privately held biotechnology company developing oral therapies for degenerative eye diseases.[[1]](https://www.theexecutivepaper.com/healthcare/20240208/joshua-s-boger-ph-d-was-appointed-as-a-director-of-cervomed-inc-and-as-chair-of-the-board-by-the-board-of-directors-11568204/index.html)[[4]](https://www.xprize.org/people/joshua-boger) Boger holds a B.A. in philosophy and chemistry from Wesleyan University and earned his M.S. and Ph.D. in chemistry from Harvard University.[[1]](https://www.theexecutivepaper.com/healthcare/20240208/joshua-s-boger-ph-d-was-appointed-as-a-director-of-cervomed-inc-and-as-chair-of-the-board-by-the-board-of-directors-11568204/index.html)[[4]](https://www.xprize.org/people/joshua-boger) His long career in biopharmaceutical leadership and drug development underpins his role as a corporate insider and director at CervoMed Inc.[[1]](https://www.theexecutivepaper.com/healthcare/20240208/joshua-s-boger-ph-d-was-appointed-as-a-director-of-cervomed-inc-and-as-chair-of-the-board-by-the-board-of-directors-11568204/index.html)[[6]](https://ir.cervomed.com/node/10611/pdf)
查看完整内部人档案 →